Canopy Growth Corp. (CGC)
Nasdaq · Medicinal Chemicals & Botanical Products · Manufacturing · CIK 1737927 · fiscal year ends in Mar
Closing price $0.65 on 30 Oct 2026; 52-week range $0.65 to $1.92.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $293.6M
- Revenue growth
- 6.8%
- Gross margin
- 25.2%
- Operating margin
- -54.9%
- Free cash flow
- -$83.2M
- Market value
- $276.8M
- Cash
- $336.6M
- Debt
- $240.2M
- Debt to equity
- 0.35
- Shares outstanding
- 423.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 31 Mar 2026 | $284.6M | -$161.7M | -$262.9M | -$0.88 | -$69.1M | 10-K filed 15 Jun 2026 |
| FY2025 | 31 Mar 2025 | $269.0M | -$117.1M | -$508.9M | -$5.56 | -$176.6M | 10-K filed 30 May 2025 |
| FY2024 | 31 Mar 2024 | $297.1M | -$228.7M | -$712.2M | -$8.79 | -$285.4M | 10-K filed 30 May 2024 |
| FY2023 | 31 Mar 2023 | $333.3M | -$2.6B | -$3.3B | -$7.07 | -$566.7M | 10-K filed 22 Jun 2023 |
| FY2022 | 31 Mar 2022 | $475.7M | -$1.0B | -$330.6M | -$0.79 | -$582.5M | 10-K filed 31 May 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q1 FY2027 | 30 Jun 2026 | $81.2M | -$14.6M | -$0.03 |
| Q4 FY2026 | 31 Mar 2026 | $71.2M | – | – |
| Q3 FY2026 | 31 Dec 2025 | $74.5M | -$62.6M | -$0.18 |
| Q2 FY2026 | 30 Sep 2025 | $66.7M | -$1.6M | -$0.01 |
| Q1 FY2026 | 30 Jun 2025 | $72.1M | -$44.9M | -$0.22 |
| Q4 FY2025 | 31 Mar 2025 | $65.0M | -$196.0M | -$1.43 |
| Q3 FY2025 | 31 Dec 2024 | $74.8M | -$98.1M | -$1.11 |
| Q2 FY2025 | 30 Sep 2024 | $63.0M | -$109.0M | -$1.48 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Cannabis | $213.9M | 75.2% |
| Storz & Bickel | $70.7M | 24.8% |
By region, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Canada | $186.1M | 65.4% |
| Germany | $62.1M | 21.8% |
| United States | $28.3M | 9.9% |
| Other | $8.2M | 2.9% |
Company events
The newest 8-K filings of 120 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 23 Oct 2026 | 8-K | Shareholder vote | 5.07 |
| 16 Oct 2026 | 8-K | Delisting notice | 3.01 |
| 7 Aug 2026 | 8-K | Auditor change | 4.01, 9.01 |
| 7 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 15 Jun 2026 | 8-K | Results | 2.02, 9.01 |
| 27 May 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 15 May 2026 | 8-K | Restatement, Investor update | 4.02, 7.01, 9.01 |
| 16 Mar 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 6 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Jan 2026 | 8-K | Material agreement, New debt, Share sale, Investor update, Other events | 1.01, 2.03, 3.02, 7.01, 8.01, 9.01 |
| 15 Dec 2025 | 8-K | Leadership change, Material agreement, Share sale, Investor update, Other events | 1.01, 3.02, 5.02, 7.01, 8.01, 9.01 |
| 7 Nov 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 498 held.
| Filed | Form | Period |
|---|---|---|
| 23 Oct 2026 | 8-K | 23 Oct 2026 |
| 16 Oct 2026 | DEFA14A | – |
| 16 Oct 2026 | 8-K | 14 Oct 2026 |
| 6 Oct 2026 | DEFA14A | – |
| 25 Sep 2026 | DEFA14A | – |
| 15 Sep 2026 | DEFA14A | – |
| 17 Aug 2026 | DEFA14A | – |
| 14 Aug 2026 | DEFA14A | – |
| 7 Aug 2026 | DEFA14A | – |
| 7 Aug 2026 | ARS | 31 Mar 2026 |
| 7 Aug 2026 | DEF 14A | 25 Sep 2026 |
| 7 Aug 2026 | 8-K | 7 Aug 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 28 Sep 2026 | Yanofsky Theresa, Director | Sale outside a trading plan | 14,920 | $0.93 | $13.8K | 131,495 | 30 Sep 2026 |
| 28 Sep 2026 | Lazzarato David Angelo, Director | Sale outside a trading plan | 22,380 | $0.93 | $20.7K | 189,479 | 30 Sep 2026 |
| 28 Sep 2026 | Bayern Joseph, Director | Sale outside a trading plan | 3,096 | $0.93 | $2.9K | 142,031 | 30 Sep 2026 |
| 28 Sep 2026 | Atkins M Shan, Director | Sale outside a trading plan | 3,096 | $0.93 | $2.9K | 143,421 | 30 Sep 2026 |
| 17 Sep 2026 | Stewart Thomas Carlton, See Remarks | Sale outside a trading plan | 25,755 | $0.93 | $24.0K | 588,412 | 17 Sep 2026 |
| 24 Aug 2026 | Gedeon Christelle, See Remarks | Sale outside a trading plan | 13,344 | $1.47 | $19.6K | 692,162 | 25 Aug 2026 |
| 24 Aug 2026 | Stewart Thomas Carlton, See Remarks | Sale outside a trading plan | 2,231 | $1.47 | $3.3K | 614,167 | 25 Aug 2026 |
| 26 Jun 2026 | Bayern Joseph, Director | Sale outside a trading plan | 3,197 | $0.92 | $3.0K | 145,127 | 29 Jun 2026 |
| 26 Jun 2026 | Yanofsky Theresa, Director | Sale outside a trading plan | 15,054 | $0.92 | $13.9K | 146,415 | 29 Jun 2026 |
| 26 Jun 2026 | Atkins M Shan, Director | Sale outside a trading plan | 3,197 | $0.92 | $3.0K | 146,517 | 29 Jun 2026 |
| 26 Jun 2026 | Lazzarato David Angelo, Director | Sale outside a trading plan | 22,674 | $0.92 | $20.9K | 211,859 | 29 Jun 2026 |
| 17 Jun 2026 | Stewart Thomas Carlton, See Remarks | Sale outside a trading plan | 9,285 | $0.97 | $9.0K | 616,398 | 22 Jun 2026 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 31.6M | +16.13% | 10.75 |
| 30 Sep 2026 | 27.2M | -2.63% | 13.03 |
| 15 Sep 2026 | 28.0M | +7.45% | 13.33 |
| 31 Aug 2026 | 26.0M | +4.15% | 5.88 |
| 14 Aug 2026 | 25.0M | +0.42% | 6.98 |
| 31 Jul 2026 | 24.9M | +7.81% | 10.86 |
| 15 Jul 2026 | 23.1M | -2.71% | 5.98 |
| 30 Jun 2026 | 23.7M | -0.65% | 5.23 |
Funds that hold it
From each fund's latest Form 13F.
246 funds held it at 30 Jun 2026: 62 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Tidal Investments LLC | 9,189,630 | $8.7M | +709,737 |
| GFS Advisors, LLC | 27 | $6.7M | +27 |
| Morgan Stanley | 1,946,294 | $1.8M | -23,346 |
| Lazard Asset Management LLC | 1,847,500 | $1.8M | +39,514 |
| Jane Street Group, LLC | 1,562,808 | $1.5M | -19,504 |
| UBS Group AG | 1,396,338 | $1.3M | +456,939 |
| Goldman Sachs Group Inc. | 1,303,720 | $1.2M | +40,118 |
| Susquehanna International Group, LLP | 1,219,106 | $1.2M | +238,530 |
| Royal Bank of Canada | 1,081,963 | $1.0M | +105,996 |
| National Bank of Canada | 858,456 | $816.0K | +48,465 |
Peers
Companies in the same industry.
- Trulieve Cannabis Corp. (TRLV): revenue $1.1B, market value $2.0B
- Cronos Group Inc. (CRON): revenue $179.1M, market value $1.2B